Anakinra, Rilonacept, and Canakinumab have been approved to treat cryopyrin-associated autoinflammatory syndrome patients 63, and Anakinra has been found to reduce inflammation and plasma glucose levels and enhance insulin secretion in diabetic patients in clinical trials 64. Here, INS is linked to autoinflammatory syndrome.